Opinion|Videos|October 25, 2024
MRD Negativity as a Trial Outcome and Its Use in Clinical Practice
Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.
Advertisement
Episodes in this series
- Dr Ajai Chari to Dr Raje: What are your thoughts on minimal residual disease negativity as a primary outcome?
- Dr Ajai Chari to Dr Rossi: For patients who are eligible for transplantation but decline, what is your treatment approach for this patient population? Do you have a preferred induction regimen?
Advertisement
Related to this article
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Zanubrutinib Plus R-BAP Elicits High Response Rates in Treatment-Naive Mantle Cell Lymphoma
5